Online citations, reference lists, and bibliographies.
← Back to Search

Impact Of Tumor-specific Targeting On The Biodistribution And Efficacy Of SiRNA Nanoparticles Measured By Multimodality In Vivo Imaging

D. Bartlett, H. Su, I. Hildebrandt, W. Weber, M. Davis
Published 2007 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Targeted delivery represents a promising approach for the development of safer and more effective therapeutics for oncology applications. Although macromolecules accumulate nonspecifically in tumors through the enhanced permeability and retention (EPR) effect, previous studies using nanoparticles to deliver chemotherapeutics or siRNA demonstrated that attachment of cell-specific targeting ligands to the surface of nanoparticles leads to enhanced potency relative to nontargeted formulations. Here, we use positron emission tomography (PET) and bioluminescent imaging to quantify the in vivo biodistribution and function of nanoparticles formed with cyclodextrin-containing polycations and siRNA. Conjugation of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid to the 5′ end of the siRNA molecules allows labeling with 64Cu for PET imaging. Bioluminescent imaging of mice bearing luciferase-expressing Neuro2A s.c. tumors before and after PET imaging enables correlation of functional efficacy with biodistribution data. Although both nontargeted and transferrin-targeted siRNA nanoparticles exhibit similar biodistribution and tumor localization by PET, transferrin-targeted siRNA nanoparticles reduce tumor luciferase activity by ≈50% relative to nontargeted siRNA nanoparticles 1 d after injection. Compartmental modeling is used to show that the primary advantage of targeted nanoparticles is associated with processes involved in cellular uptake in tumor cells rather than overall tumor localization. Optimization of internalization may therefore be key for the development of effective nanoparticle-based targeted therapeutics.
This paper references
Bioconjugate Chem 18:456–468
DW Bartlett (2007)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
10.1002/BIT.21285
Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA‐mediated gene silencing
D. Bartlett (2007)
10.1162/15353500200303133
AMIDE: A Free Software Tool for Multimodality Medical Image Analysis
A. Loening (2003)
Cancer Res
Db Kirpotin (2006)
Bioconjugate Chem
Dw Bartlett (2007)
[General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics].
Y. Matsumura (1987)
Phys Med Biol
Pl Chow (2006)
J Physiol
Ac Riches (1973)
Nat Med
Z Medarova (2007)
10.1038/nm1486
In vivo imaging of siRNA delivery and silencing in tumors
Z. Medarova (2007)
Cancer Res
Pt Yazdi (1995)
Int J Pharm
Hk De Wolf (2007)
10.1113/jphysiol.1973.sp010086
Blood volume determination in the mouse
A. C. Riches (1973)
10.1016/J.NUCMEDBIO.2007.02.006
Radiolabeling small RNA with technetium-99m for visualizing cellular delivery and mouse biodistribution.
N. Liu (2007)
10.1038/nature03121
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J. Soutschek (2004)
10.1021/BC0603539
Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
D. Bartlett (2007)
10.1016/j.otohns.2009.05.016
Nature
R. Rosenfeld (2009)
10.1088/0031-9155/51/2/013
A method of image registration for small animal, multi-modality imaging.
P. Chow (2006)
Bioorgan Med Chem
Da Braasch (2004)
Drug Metab Dispos 34:1393–1397
FM van de Water (2006)
Cancer Biol Ther
Sh Pun (2004)
Am J Roentgenol
Bs Kuszyk (2001)
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
G. Adams (1998)
10.1038/nbt1101
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Erwei Song (2005)
Proc Natl Acad Sci
Am Wu (2000)
10.1016/J.IJPHARM.2006.10.029
Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration.
Holger K. de Wolf (2007)
10.1248/BPB.29.1936
Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs.
N. Maeda (2006)
10.1016/J.BMCL.2003.12.074
Biodistribution of phosphodiester and phosphorothioate siRNA.
D. A. Braasch (2004)
Gene Ther
M Ogris (1999)
Cancer Res
Gp Adams (1998)
10.1152/AJPLEGACY.1970.218.1.88
Release of copper by rat liver.
C. A. Owen (1970)
10.2214/AJR.177.4.1770747
Tumor transport physiology: implications for imaging and imaging-guided therapy.
B. Kuszyk (2001)
Gene Ther 8:28–40
R Kircheis (2001)
Gene Ther
R Kircheis (2001)
10.1158/0008-5472.CAN-05-4199
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
10.1038/nature04688
RNAi-mediated gene silencing in non-human primates
T. Zimmermann (2006)
10.1093/nar/gkj439
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging
D. Bartlett (2006)
Gene Ther 6:595–605
M Ogris (1999)
10.1038/sj.cgt.7700487
Tumor-targeted gene delivery of tumor necrosis factor-α induces tumor necrosis and tumor regression without systemic toxicity
R. Kircheis (2002)
10.1158/0008-5472.CAN-05-0565
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma.
S. Hu-Lieskovan (2005)
Clin Cancer Res
Jw Park (2002)
Nat Biotechnol
E Song (2005)
10.1073/PNAS.150228297
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.
A. Wu (2000)
10.1124/dmd.106.009555
INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES
F. M. van de Water (2006)
Biol Pharm Bull
N Maeda (2006)
Nucleic Acids Res Biotechnol Bioeng Loening AM, Gambhir SS Mol Imaging Am J Physiol Drug Metab Dispos
Dw Bartlett (1970)
10.1038/sj.gt.3300900
PEGylated DNA/transferrin–PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery
M. Ogris (1999)
Cancer Gene Ther
R Kircheis (2002)
Mol Ther
Ma Behlke (2006)
Gan To Kagaku Ryoho
Y Matsumura (1987)
Cancer Res
S Hu-Lieskovan (2005)
10.1038/sj.gt.3301351
Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application
R. Kircheis (2001)
Influence of cellular trafficking on protein synthesis inhibition of immunotoxins directed against the transferrin receptor.
P. Yazdi (1995)
Nucl Med Biol
N Liu (2007)



This paper is referenced by
10.1117/1.3449109
Imaging targeted-agent binding in vivo with two probes.
B. Pogue (2010)
10.1186/1758-907X-1-14
A status report on RNAi therapeutics
A. Vaishnaw (2010)
10.1371/journal.pone.0065623
Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting
K. Tsekouras (2013)
10.1021/ar500055s
Cyclodextrin-based host-guest supramolecular nanoparticles for delivery: from design to applications.
Q. Hu (2014)
ReviewA status report on RNAi therapeutics
A. Vaishnaw (2015)
10.1021/nn200876f
Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia.
Zhiyong Poon (2011)
10.1016/j.ijpharm.2016.10.013
Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
M. van Elk (2016)
10.1016/j.addr.2010.03.011
Tumor delivery of macromolecular drugs based on the EPR effect.
V. Torchilin (2011)
10.1016/j.biomaterials.2011.01.006
A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy.
Cheng-qiong Mao (2011)
10.1038/nrd2742
Knocking down barriers: advances in siRNA delivery
K. Whitehead (2009)
10.1007/978-1-60327-321-3_13
Quantitative in vivo imaging of non-viral-mediated gene expression and RNAi-mediated knockdown.
Garrett R Rettig (2009)
10.1038/ncomms11221
Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
Yiming Zhao (2016)
10.1016/j.jconrel.2015.10.050
Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes.
Yuvraj Singh (2015)
10.1016/j.nano.2017.09.012
Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
J. Wang (2018)
Copper- 6 4cals for Oncologic Imaging
J. Holland (2009)
Bioengineering targeted nanodrugs for hematologic malignancies: An innovation in pediatric oncology
V. Krishnan (2015)
10.1016/j.jconrel.2011.12.038
Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
A. L. Petersen (2012)
10.1016/j.biomaterials.2011.11.079
Supramolecular assemblies in functional siRNA delivery: where do we stand?
Hamidreza M. Aliabadi (2012)
10.2174/138920012798356899
The ligand nanoparticle conjugation approach for targeted cancer therapy.
Nour Karra (2012)
Development of nanoscale delivery systems for breast cancer treatment
Y. Zhang (2015)
Activatable cell penetrating peptides and their use in clinical contrast agent and therapeutic development
Todd A. Aguilera (2009)
10.1016/j.addr.2009.04.001
Delivery of RNA interference therapeutics using polycation-based nanoparticles.
K. Howard (2009)
10.2147/IJN.S78995
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
S. Capolla (2015)
Development of nanoparticle platform for therapeutic siRNA and drug delivery to breast cancer
Worapol Ngamcherdtrakul (2015)
10.6004/JNCCN.2014.0175
Nanotechnologies in cancer treatment and diagnosis.
Stephanie A. Morris (2014)
10.1002/9781444329896.CH7
Perspectives on Nanotechnology
Aleksandar F. Radovic-Moreno (2011)
10.1016/j.nucmedbio.2010.08.008
Unexpected side products in the conjugation of an amine-derivatized morpholino oligomer with p-isothiocyanate benzyl DTPA and their removal.
G. Liu (2011)
10.1039/c6nr01595f
Hierarchical design of a polymeric nanovehicle for efficient tumor regression and imaging.
Jinxia An (2016)
10.1371/journal.pone.0072938
A Liposomal Drug Platform Overrides Peptide Ligand Targeting to a Cancer Biomarker, Irrespective of Ligand Affinity or Density
B. Gray (2013)
10.1016/j.jconrel.2011.07.035
Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Xian-Zhu Yang (2011)
10.2217/nnm.13.222
Biocompatible surface-enhanced Raman scattering nanotags for in vivo cancer detection.
A. Samanta (2014)
10.1073/pnas.1315336110
Photoswitchable nanoparticles for in vivo cancer chemotherapy
R. Tong (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar